Results 31 to 40 of about 1,016,101 (284)
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Acta Pharmaceutica Sinica B, 2018 Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao +4 more
doaj +1 more source
Gene modification strategies for next-generation CAR T cells against solid cancers
Journal of Hematology & Oncology, 2020 Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies.
Yonggui Tian +3 more
doaj +1 more source
Nature Communications, 2023 Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.
Elisa Ruffo +10 more
doaj +1 more source
Frontiers in Immunology, 2019 Immune cell therapies based on the integration of synthetic antigen receptors comprise a powerful strategy for the treatment of diverse diseases, most notably T cells engineered to express chimeric antigen receptors (CAR) for targeted cancer therapy.
Theresa Pesch +9 more
doaj +1 more source
Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.
PLoS ONE, 2013 Transfer of tumour antigen-specific receptors to T cells requires efficient delivery and integration of transgenes, and currently most clinical studies are using gamma retroviral or lentiviral systems.
Anne-Christine Field +9 more
doaj +1 more source
Chimeric Antigen Receptor Therapy
New England Journal of Medicine, 2018 Chimeric Antigen Receptor T Cells This review addresses T-cell engineering and synthetic immunity, with a focus on producing durable remissions in patients with treatment-refractory tumors.
Carl H. June, Michel Sadelain
openaire +3 more sources
EXPRESSION OF A FUNCTIONAL CHIMERIC lg-MHC CLASS II PROTEIN [PDF]
, 1992 composed of the a- and ß-chains of the MHC class I1 I-E molecule fused to antibody V regions derived from anti-human CD4 mAb MT310. Expression vectors were constructed containing the functional, rearranged gene segments coding for the V region domains of
Zwirner, Jörg +8 more
core +1 more source
Cell Transplantation, 2022 Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang +7 more
doaj +1 more source
Structure‐forward targeting of claudins with synthetic binders
FEBS Letters, EarlyView.Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
, 2019 Background: Immunotherapy utilizing T cells genetically modified to express chimeric antigen receptors (CARs) is rapidly emerging as a promising novel treatment for hematological and nonhematological malignancies.
Na Shen (110593) +9 more
core +1 more source